Shorla Patent-Cliff Exposure & CMS Drug Spending Portfolio

Shorla (US): 2 reconciled FDA prescription therapies, $6K 2024 CMS Part D & Medicaid spend, and $3,714 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$6K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$6K
California HCAI SB 17 FilingsSpecialty launch notice ($3,714 intro WAC)